Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01207453 · ClinicalTrials.gov registry record · Phase 4
Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis
A Phase 4 study, sponsored by Brigham and Women's Hospital.
- Completed
- Registry status
- Phase 4
- Development phase
- 49
- Enrollment target
NCT01207453 is a Phase 4 study that has completed, run by Brigham and Women's Hospital. The registered enrollment target is 49 participants.
The verdict
NCT01207453, a Phase 4 study, has completed, sponsored by Brigham and Women's Hospital.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 49 participants
- Enrollment target
Study Summary
The purpose of this study is to determine whether milnacipran reduces widespread, non-joint pain in patients with rheumatoid arthritis (RA). The investigators will conduct a double-blind randomized crossover trial in subjects with RA to test the hypothesis that milnacipran improves widespread, non-joint pain. The investigators will also use data from the trial to determine whether response to milnacipran is associated with pain-modulating mechanisms from the central nervous system. The investigators hypothesize that response to milnacipran will be greater among patients with impaired central pain mechanisms than among patients with intact central pain modulating mechanisms.
Interventions
- DRUG Placebo
- DRUG Milnacipran
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 49 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01207453
The ClinicalTrials.gov registry entry for NCT01207453 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 49 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Brigham and Women's Hospital, which has 937 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01207453 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01207453 about?
NCT01207453 is a clinical study titled "Milnacipran in the Treatment of Widespread, Non-Joint Pain in Rheumatoid Arthritis". The purpose of this study is to determine whether milnacipran reduces widespread, non-joint pain in patients with rheumatoid arthritis (RA). The investigators will conduct a double-blind randomized crossover trial in subjects with RA to test the hypothesis that milnacipran improves widespread, non-j...
What is the current status of trial NCT01207453?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 49 participants. The study started on 2011-01. Estimated completion is 2013-11.
What interventions are being tested in trial NCT01207453?
The interventions under investigation include: Placebo (DRUG), Milnacipran (DRUG).
Who is sponsoring clinical trial NCT01207453?
This trial is sponsored by Brigham and Women's Hospital, which has 937 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.